Related Experiment Video
Updated: Jul 11, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
[Diabetes mellitus and heart failure]
M Füchtenbusch1, E Standl, W Otter
1Inst. für Diabetesforschung & Klinik für Endokrinologie, Diabetologie und Suchtmedizin, Krankenhaus Schwabing, München. Martin.Fuchtenbusch@gmx.de
Insights
Patients with diabetes mellitus (DM) and chronic heart failure (CHF) face poor prognoses. Effective management requires standard CHF treatments, strict glucose control, and consideration of antidiabetic drug contraindications.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Diseases
Context:
- Diabetes mellitus (DM) is a significant risk factor for chronic heart failure (CHF), affecting 10-15% of DM patients compared to 3% in non-DM individuals.
- Hyperglycemia and insulin resistance in DM are directly implicated in the pathogenesis of diastolic dysfunction and CHF.
- The co-occurrence of DM and CHF presents a complex clinical challenge with a poor prognosis.
Purpose:
- To outline the epidemiology, pathophysiology, diagnosis, and management of chronic heart failure (CHF) in patients with diabetes mellitus (DM).
- To emphasize the importance of integrated care addressing both glycemic control and cardiovascular management.
- To highlight specific considerations for antidiabetic medication use in CHF patients.
Summary:
- DM is an independent risk factor for CHF, with higher prevalence and poorer outcomes in affected patients.
- Diagnosis follows established guidelines, including ECG, natriuretic peptide testing, and echocardiography.
- Standard CHF pharmacotherapy (ACEIs, ARBs, BBs, diuretics, etc.) is indicated, alongside meticulous glucose control.
- Certain antidiabetic drugs (glitazones, metformin) have contraindications based on CHF severity (NYHA classes).
Impact:
- Improved understanding of the bidirectional relationship between DM and CHF.
- Guidance on diagnostic and therapeutic strategies for this high-risk patient population.
- Emphasis on personalized treatment considering both diabetes and heart failure status, including medication safety.
Abstract:
Chronic heart failure (CHF) in patients with diabetes mellitus (DM) is a condition that is frequent and has a poor prognosis. Diabetes mellitus is an independent risk factor for CHF and vice versa. CHF is found in 10-15% of the patients with DM compared to 3% in individuals without DM. Apart from CHD and hypertension, hyperglycaemia and insulin resistance are directly linked to the development of diastolic dysfunction and to CHF. According to the stepwise diagnostic procedure recommended by the ESC in its guidelines from 2005, if heart failure is suspected, the disease should first be diagnosed by ECG, X-ray, or testing for natriuretic peptide and followed by echocardiography when test results are abnormal. Treatment of CHF in patients with diabetes mellitus is the same as that for nondiabetic patients and includes the use of ACEIs, ARBSs (as an alternative to or in combination with ACEIs), BBs, diuretics (in particular loop diuretics), aldosterone inhibitors and digitalis. Most importantly, meticulous glucose control is a must in patients with diabetes mellitus and CHF to improve prognosis. Contraindications for antidiabetic drugs such as glitazones for CHF-NYHA classes I-IV and metformin for NYHA classes III-IV need to be considered in patients with CHF and diabetes mellitus.
Related Concept Videos
Heart Failure I: Introduction
Pathophysiology of Heart Failure
Heart Failure Drugs: Diuretics
Heart Failure II: Pathophysiology
Complications of Diabetes Mellitus
Heart Failure IV: Classification and Diagnostic Evaluation
